智通财经APP获悉，礼来 (LLY.US)今日 (10月30日)宣布TRAILBLAZER-ALZ 6临床3b期研究达成主要终点。在24周时，具有早期症状的 阿尔茨海默病 (AD)成人患者在接受经调整的Kisunla (donanemab)给药方案后 ...

"Donanemab demonstrated meaningful results for people with early symptomatic Alzheimer's disease by significantly slowing ...

Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...

Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...

"I have an LVAD 3 and I hate having to carry the required equipment at all times. I thought there could be a modified garment to safely and conveniently hold the equipment," said an inventor, from ...

印第安纳波利斯 - 礼来公司(NYSE: LLY)公布了其最新的3b期研究结果,显示早期症状性阿尔茨海默病患者中与淀粉样蛋白相关的成像异常伴水肿/渗出(ARIA-E)的发生率有所降低。这项名为TRAILBLAZER-ALZ ...

Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a ...

With new therapies available to treat early stages of Alzheimer disease, recognizing the symptoms earlier is increasingly important.

Two novel drugs for treating Alzheimer's have been rejected for use on the NHS, despite gaining approval from the UK ...

The standard dosing regimen was 700 mg of donanemab for the first three infusions, then 1,400 mg for each infusion after that ...

The UK's drugs regulator - the MHRA - has approved the Alzheimer's drug donanemab, but it won't be available on the ...

The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.